Wednesday, July 8, 2026

Patent intelligence · US

US 11052064

Compositions, methods and systems for the treatment of cutaneous disorders

granted A61KA61K2800/42A61K31/34A61K31/343
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 15
Applicant portfolio 7
Patent details — US 11052064
Jurisdiction
US
Status
granted
Grant date
Jul 6, 2021
Expiration
Jul 1, 2041
Claims
48
CPC classes
A61K, A61K2800/42, A61K31/34, A61K31/343
View on Google Patents ↗

Quick answer

US 11052064 (Compositions, methods and systems for the treatment of cutaneous disorders) is held by Verrica Pharmaceuticals Inc.. Status: granted. Granted Jul 6, 2021. Expires Jul 1, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
48
CPC classes
A61K, A61K2800/42, A61K31/34, A61K31/343, A61K47/10, A61K47/20

More from Verrica Pharmaceuticals Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12290651

    Devices and methods for the treatment of body surface disorders

    Verrica Pharmaceuticals Inc. · Expires May 1, 2045

    granted
  2. US 12233042

    Treatment of cutaneous disorders

    Verrica Pharmaceuticals Inc. · Expires Feb 20, 2045

    granted
  3. US 12221452

    Synthesis of cantharidin

    Verrica Pharmaceuticals Inc. · Expires Feb 6, 2045

    granted
  4. US 11168091

    Quantification and preparation of pharmaceutical grade cantharidin

    Verrica Pharmaceuticals Inc. · Expires Nov 4, 2041

    granted
  5. US 11147790

    Treatment of cutaneous disorders

    Verrica Pharmaceuticals Inc. · Expires Oct 14, 2041

    granted
  6. US 10745413

    Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives

    Verrica Pharmaceuticals Inc. · Expires Aug 13, 2040

    granted

Frequently asked questions

What is US patent 11052064?

US 11052064 (Compositions, methods and systems for the treatment of cutaneous disorders) is held by Verrica Pharmaceuticals Inc.. Status: granted. Granted Jul 6, 2021. Expires Jul 1, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11052064?

Verrica Pharmaceuticals Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.

When does US 11052064 expire?

Our index shows an expiration date of Jul 1, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.